Compare WINA & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WINA | IMNM |
|---|---|---|
| Founded | 1988 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.8B |
| IPO Year | 1993 | 2020 |
| Metric | WINA | IMNM |
|---|---|---|
| Price | $404.96 | $21.46 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $31.44 |
| AVG Volume (30 Days) | 82.0K | ★ 3.0M |
| Earning Date | 02-18-2026 | 11-06-2025 |
| Dividend Yield | ★ 2.80% | N/A |
| EPS Growth | ★ 2.56 | N/A |
| EPS | ★ 11.21 | N/A |
| Revenue | ★ $84,517,400.00 | $9,679,000.00 |
| Revenue This Year | $7.05 | N/A |
| Revenue Next Year | $3.60 | $11.53 |
| P/E Ratio | $36.11 | ★ N/A |
| Revenue Growth | ★ 3.35 | N/A |
| 52 Week Low | $295.79 | $5.15 |
| 52 Week High | $527.37 | $25.30 |
| Indicator | WINA | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 41.39 | 56.28 |
| Support Level | $398.07 | $21.00 |
| Resistance Level | $420.04 | $22.57 |
| Average True Range (ATR) | 15.41 | 1.41 |
| MACD | -2.09 | -0.11 |
| Stochastic Oscillator | 12.06 | 40.99 |
Winmark Corp is a franchisor of value-oriented retail store concepts that buy, sell, and trade gently used merchandise. The company has one reportable segment including Franchising and one non-reportable segment Leasing. The franchising segment franchises value-oriented retail store that buys, sell, trade, and consign merchandise as well as provide strategic consulting services relating to franchising. The leasing segment includes middle-market equipment leasing business and small-ticket financing business. It generates a majority of its revenue from the Franchising segment.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.